<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">KREJCI, DANIEL</style></author><author><style face="normal" font="default" size="100%">OPALKA, PETR</style></author><author><style face="normal" font="default" size="100%">KREJCI, JANA</style></author><author><style face="normal" font="default" size="100%">ZEMANOVA, MILADA</style></author><author><style face="normal" font="default" size="100%">ZEMANOVA, PETRA</style></author><author><style face="normal" font="default" size="100%">KULTAN, JURAJ</style></author><author><style face="normal" font="default" size="100%">FISCHER, ONDREJ</style></author><author><style face="normal" font="default" size="100%">SKRICKOVA, JANA</style></author><author><style face="normal" font="default" size="100%">BRATOVA, MONIKA</style></author><author><style face="normal" font="default" size="100%">CERNOVSKA, MARKETA</style></author><author><style face="normal" font="default" size="100%">HRNCIARIK, MICHAL</style></author><author><style face="normal" font="default" size="100%">COUPKOVA, HELENA</style></author><author><style face="normal" font="default" size="100%">HURDALKOVA, KAROLINA</style></author><author><style face="normal" font="default" size="100%">BARINOVA, MAGDA</style></author><author><style face="normal" font="default" size="100%">KOUBKOVA, LEONA</style></author><author><style face="normal" font="default" size="100%">DOLEZAL, DANIEL</style></author><author><style face="normal" font="default" size="100%">SAFANDA, MARTIN</style></author><author><style face="normal" font="default" size="100%">PESEK, MILOS</style></author><author><style face="normal" font="default" size="100%">SVATON, MARTIN</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">2597-2603</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.15039</style></doi><volume><style face="normal" font="default" size="100%">41</style></volume><issue><style face="normal" font="default" size="100%">5</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab are regimens used in combination with checkpoint inhibitors in non-squamous non-small cell lung cancer (NSCLC) treatment. We conducted a real-world study to compare the outcomes of these chemotherapeutic regimens. Patients and Methods: We investigated 1,534 patients with advanced non-squamous NSCLC treated with platin/pemetrexed (n=1212) or platin/paclitaxel/bevacizumab (n=322) in 9 cancer centres in the Czech Republic. Results: The regimen containing platin/paclitaxel/bevacizumab showed significantly better overall response rate (ORR) compared to the platin/pemetrexed [40.8% vs. 32.7% (p=0.008)] in the overall population and [55.0% vs. 38.8% (p=0.002)] in the Eastern Cooperative Oncology Group performance status 0 group. There was no significant improvement in progression-free survival (PFS) and overall survival (OS) in either of these two groups of patients. Conclusion: In our real-world data analysis, patients treated with platin/paclitaxel/bevacizumab had better overall response rate (ORR), but not PFS or OS. Thus, both treatment regimens are similarly effective. Their selection should therefore be based on the potential side effects.</style></abstract></record></records></xml>